NeogenNEOG +0.27%68 EV-to-FCF is 440.81 as of Jul. 04, 2026, which is 681% above its 10-year median of 56.44. GuruFocus rates NEOG with a GF Score™ of 68/100 and a GF Value™ of $12.30 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Neogen ranks worse than 96.89% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Neogen's Enterprise Value is $2,666.5 Mil.
Neogen's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 was $6.0 Mil. Therefore, Neogen's EV-to-FCF for today is 440.81.
The historical rank and industry rank for Neogen's EV-to-FCF or its related term are showing as below:
NEOG'
s EV-to-FCF Range Over the Past 10 Years
Min: -1095.49 Med: 56.44 Max: 453.76
Current: 440.81
During the past 13 years, the highest EV-to-FCF of Neogen was 453.76. The lowest was -1095.49. And the median was 56.44.
NEOG's EV-to-FCF is ranked worse than 96.89% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 23.12
vs NEOG: 440.81
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-04), Neogen's stock price is $9.34.
Neogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 was $-2.801. Therefore, Neogen's PE Ratio (TTM) for today is At Loss.
Neogen (NAS:NEOG) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neogen's share price for today is $9.34.
Neogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.801.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Neogen EV-to-FCF Related Terms
Neogen EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Neogen's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Neogen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Neogen's EV-to-FCF falls into.
Neogen's current Enterprise Value is $2,666.5 Mil.
Neogen's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (NEOG) has a EV-to-FCF of 440.81 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Neogen and its competitors. This is 681% above median its historical median of 56.44. According to the industry distribution chart, Neogen ranks #405 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 96.9%.
Is Neogen's EV-to-FCF too high?
Neogen's current EV-to-FCF of 440.81 is 681% above median its 10-year median of 56.44. The Medical Devices & Instruments industry median EV-to-FCF is 23.12. Neogen's value of 440.81 is 1806.6% above this industry median. Based on the distribution chart, Neogen ranks #405 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's EV-to-FCF compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #405 out of 418 companies for EV-to-FCF. This places Neogen in the lower half of its industry. The industry median EV-to-FCF is 23.12. Neogen's value of 440.81 is 1806.6% above this benchmark. While the company's 10-year median is 56.44 vs. the industry median of 23.12, Neogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.12, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current EV-to-FCF of 440.81 is 1806.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current EV-to-FCF is 440.81, which is 681% above median its own 10-year median of 56.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (NEOG) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.30, compared to a current price of $9.34 — trading 24.1% below its estimated fair value. The current EV-to-FCF is 440.81, which is 681% above median its 10-year median of 56.44 and 1806.6% above the Medical Devices & Instruments industry median of 23.12. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Neogen (NEOG), the current EV-to-FCF is 440.81 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (NEOG) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of $9.34 is trading 24.1% below its estimated GF Value™ of $12.30.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for NEOG:
EV-to-FCF: 440.81 (681% above median its 10-year median of 56.44)
GF Value™: $12.30 vs. price of $9.34 (24.1% below fair value)
Industry Position: 1806.6% above the Medical Devices & Instruments median (#405 of 418)
No single metric tells the full story. See the NEOG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for NEOG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEOG has been successfully added to your 
